- Home
- ABP vs TENX Comparison
ABP vs TENX Comparison
Compare ABP & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABP
- TENX
- Stock Information
- Founded
- ABP 2004
- TENX 1967
- Country
- ABP United States
- TENX United States
- Employees
- ABP N/A
- TENX N/A
- Industry
- ABP Biotechnology: Pharmaceutical Preparations
- TENX Biotechnology: Pharmaceutical Preparations
- Sector
- ABP Health Care
- TENX Health Care
- Exchange
- ABP Nasdaq
- TENX Nasdaq
- Market Cap
- ABP 26.5M
- TENX 21.7M
- IPO Year
- ABP N/A
- TENX N/A
- Fundamental
- Price
- ABP $0.41
- TENX $6.30
- Analyst Decision
- ABP Strong Buy
- TENX Strong Buy
- Analyst Count
- ABP 1
- TENX 3
- Target Price
- ABP $4.00
- TENX $16.00
- AVG Volume (30 Days)
- ABP 57.0K
- TENX 20.7K
- Earning Date
- ABP 05-18-2025
- TENX 05-13-2025
- Dividend Yield
- ABP N/A
- TENX N/A
- EPS Growth
- ABP N/A
- TENX N/A
- EPS
- ABP N/A
- TENX N/A
- Revenue
- ABP $230,000.00
- TENX N/A
- Revenue This Year
- ABP N/A
- TENX N/A
- Revenue Next Year
- ABP N/A
- TENX N/A
- P/E Ratio
- ABP N/A
- TENX N/A
- Revenue Growth
- ABP N/A
- TENX N/A
- 52 Week Low
- ABP $0.40
- TENX $2.77
- 52 Week High
- ABP $13.00
- TENX $7.89
- Technical
- Relative Strength Index (RSI)
- ABP N/A
- TENX 49.26
- Support Level
- ABP N/A
- TENX $6.00
- Resistance Level
- ABP N/A
- TENX $6.76
- Average True Range (ATR)
- ABP 0.00
- TENX 0.40
- MACD
- ABP 0.00
- TENX 0.02
- Stochastic Oscillator
- ABP 0.00
- TENX 39.47
About ABP Abpro Holdings Inc Common Stock
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms, The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with global pharmaceutical and research institutions.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.